Quinolone-containing therapies in the eradication of Helicobacter pylori

Seng-Kee Chuah, Wei-Chen Tai, Chen-Hsiang Lee, Chih-Ming Liang, Tsung-Hui Hu, Seng-Kee Chuah, Wei-Chen Tai, Chen-Hsiang Lee, Chih-Ming Liang, Tsung-Hui Hu

Abstract

Fluoroquinolones, especially levofloxacin, are used in the eradication of Helicobacter pylori worldwide. Many consensus guidelines recommend that the second-line rescue therapy for H. pylori eradication consists of a proton pump inhibitor, a quinolone, and amoxicillin as an option. Unfortunately, quinolone is well associated with a risk of developing bacterial resistance. In this paper, we review quinolone-containing H. pylori eradication regimens and the challenges that influence the efficacy of eradication. It is generally suggested that the use of levofloxacin should be confined to "rescue" therapy only, in order to avoid a further rapid increase in the resistance of H. pylori to quinolone. The impact of quinolone-containing H. pylori eradication regimens on public health issues such as tuberculosis treatment must always be taken into account. Exposure to quinolone is relevant to delays in diagnosing tuberculosis and the development of drug resistance. Extending the duration of treatment to 14 days improves eradication rates by >90%. Tailored therapy to detect fluoroquinolone-resistant strains can be done by culture-based and molecular methods to provide better eradication rates. Molecular methods are achieved by using a real-time polymerase chain reaction to detect the presence of a gyrA mutation, which is predictive of treatment failure with quinolones-containing triple therapy.

References

    1. Matsumoto Y, Miki I, Aoyama N, et al. Levofloxacin- versus metronidazole-based rescue therapy for H. pylori infection in Japan. Digestive and Liver Disease. 2005;37(11):821–825.
    1. Chuah SK, Tsay FW, Hsu PI, Wu DC. A new look at anti-Helicobacter pylori therapy. World Journal of Gastroenterology. 2011;17(35):3971–3975.
    1. Chey WD, Wong BCY. American College of Gastroenterology guideline on the management of Helicobacter pylori infection. The American Journal of Gastroenterology. 2007;102(8):1808–1825.
    1. Fock KM, Katelaris P, Sugano K, et al. Second Asia-Pacific Consensus Guidelines for Helicobacter pylori infection. Journal of Gastroenterology and Hepatology. 2009;24(10):1587–1600.
    1. Malfertheiner P, Megraud F, O'Morain CA, et al. Management of Helicobacter pylori infection—the Maastricht IV/ Florence consensus report. Gut. 2012;61(5):646–664.
    1. Chuah SK, Hsu PI, Chang KC, et al. Randomized comparison of two non-bismuth-containing second-line rescue therapies for Helicobacter pylori . Helicobacter. 2012;17(3):216–223.
    1. Chuah SK, Tai WC, Hsu PI, et al. The efficacy of second-line anti-Helicobacter pylori therapy using an extended 14-days’ levofloxacin/amoxicillin/protonpump inhibitors—a pilot study. Helicobacter. 2012;17:374–381.
    1. de Sarro A, de Sarro G. Adverse reactions to fluoroquinolones: an overview on mechanistic aspects. Current Medicinal Chemistry. 2001;8(4):371–384.
    1. Tanaka M, Isogai E, Isogai H, et al. Synergic effect of quinolone antibacterial agents and proton pump inhibitors on Helicobacter pylori . Journal of Antimicrobial Chemotherapy. 2002;49(6):1039–1040.
    1. Goh KL, Navaratnam P. High Helicobacter pylori resistance to metronidazole but zero or low resistance to clarithromycin, levofloxacin, and other antibiotics in Malaysia. Helicobacter. 2011;16(3):241–245.
    1. Murakami K, Furuta T, Ando T, et al. Multi-center randomized controlled study to establish the standard third-line regimen for Helicobacter pylori eradication in Japan. Journal of Gastroenterology. 2013;48(10):1128–1135.
    1. Robicsek A, Jacoby GA, Hooper DC. The worldwide emergence of plasmid-mediated quinolone resistance. The Lancet Infectious Diseases. 2006;6(10):629–640.
    1. Su P, Li Y, Li H, et al. Antibiotic resistance of Helicobacter pylori isolated in the Southeast Coastal Region of China. Helicobacter. 2013;18(4):274–279.
    1. Binh TT, Shiota S, Nguyen LT, et al. The incidence of primary antibiotic resistance of Helicobacter pylori in Vietnam. Journal of Clinical Gastroenterology. 2013;47(3):233–238.
    1. Rajper S, Khan E, Ahmad Z, Alam SMZ, Akbar A, Hasan R. Macrolide and fluoroquinolone resistance in Helicobacter pylori isolates: an experience at a tertiary care centre in Pakistan. Journal of the Pakistan Medical Association. 2012;62(11):1140–1144.
    1. Wueppenhorst N, Stueger H, Kist M, Glocker E. High secondary resistance to quinolones in German Helicobacter pylori clinical isolates. Journal of Antimicrobial Chemotherapy. 2013;68(7):1562–1566.
    1. Almeida N, Romãozinho JM, Donato MM, et al. Helicobacter pylori antimicrobial resistance rates in the central region of Portugal. Clinical Microbiology and Infection. 2014
    1. Tveit AH, Bruce MG, Bruden DL, et al. Alaska sentinel surveillance study of Helicobacter pylori isolates from Alaska native persons from 2000 to 2008. Journal of Clinical Microbiology. 2011;49(10):3638–3643.
    1. Eisig JN, Silva FM, Barbuti RC, Navarro-Rodriguez T, Moraes-Filho JPP, Pedrazzoli J., Jr. Helicobacter pylori antibiotic resistance in Brazil: Clarithromycin is still a good option. Arquivos de Gastroenterologia. 2011;48(4):261–264.
    1. Tai WC, Lee CH, Chiou SS. The clinical and bacteriological factors for optimal levofloxacin-containing triple therapy in second-line Helicobacter pylori eradication. PLoS ONE. 2014;9(8)e105822
    1. Greenberg ER, Anderson GL, Morgan DR, et al. 14-day triple, 5-day concomitant, and 10-day sequential therapies for Helicobacter pylori infection in seven Latin American sites: a randomised trial. The Lancet. 2011;378(9790):507–514.
    1. Laine L, Hunt R, EI-Zimaity H, Nguyen B, Osato M, Spénard J. Bismuth-based quadruple therapy using a single capsule of bismuth biskalcitrate, metronidazole, and tetracycline given with omeprazole versus omeprazole, amoxicillin, and clarithromycin for eradication of Helicobacter pylori in duodenal ulcer patients: a prospective, randomized, multicenter, North American trial. The American Journal of Gastroenterology. 2003;98(3):562–567.
    1. Vaira D, Zullo A, Vakil N, et al. Sequential therapy versus standard triple-drug therapy for Helicobacter pylori eradication: a randomized trial. Annals of Internal Medicine. 2007;146(8):556–563.
    1. Liou JM, Chen CC, Chen MJ, et al. Sequential versus triple therapy for the first-line treatment of Helicobacter pylori: a multicentre , open-label, randomized trial. The Lancet. 2013;381:205–213.
    1. Zullo A, Gatta L, de Francesco V, et al. High rate of Helicobacter pylori eradication with sequential therapy in elderly patients with peptic ulcer: a prospective controlled study. Alimentary Pharmacology and Therapeutics. 2005;21(12):1419–1424.
    1. Seddik H, Ahid S, El Adioui T, et al. Sequential therapy versus standard triple-drug therapy for Helicobacter pylori eradication: a prospective randomized study. European Journal of Clinical Pharmacology. 2013;69(9):1709–1715.
    1. Liu KS, Hung IF, Seto WK, et al. Ten day sequential versus 10 day modified bismuth quadruple therapy as empirical firstline and secondline treatment for Helicobacter pylori in Chinese patients: an open label, randomised, crossover trial. Gut. 2014;63(9):1410–1415.
    1. Kim JS, Kim BW, Ham JH, et al. Sequential therapy for Helicobacter pylori infection in Korea: systematic review and meta-analysis. Gut Liver. 2013;7:546–551.
    1. Fakheri H, Taghvaei T, Hosseini V, Bari Z. A comparison between sequential therapy and a modified bismuth-based quadruple therapy for Helicobacter pylori eradication in iran: a randomized clinical trial. Helicobacter. 2012;17(1):43–48.
    1. Sirimontaporn N, Thong-Ngam D, Tumwasorn S, Mahachai V. Ten-day sequential therapy of Helicobacter pylori infection in thailand. The American Journal of Gastroenterology. 2010;105(5):1071–1075.
    1. Wu DC, Hsu PI, Wu JY, et al. Sequential and concomitant therapy with four drugs is equally effective for eradication of H pylori infection. Clinical Gastroenterology and Hepatology. 2010;8:36–41.
    1. Essa AS, Kramer JR, Graham DY, Treiber G. Meta-analysis: four-drug, three-antibiotic, non-bismuth-containing “concomitant therapy” versus triple therapy for Helicobacter pylori eradication. Helicobacter. 2009;14(2):109–118.
    1. Hsu PI, Wu DC, Wu JY, Graham DY. Modified sequential Helicobacter pylori therapy: proton pump inhibitor and amoxicillin for 14 days with clarithromycin and metronidazole added as a quadruple (hybrid) therapy for the final 7 days. Helicobacter. 2011;16(2):139–145.
    1. Wu TS, Hu HM, Kuo FC, Kuo CH. Eradication of Helicobacter pylori infection. Kaohsiung Journal of Medical Sciences. 2014;30:167–172.
    1. Berning M, Krasz S, Miehlke S. Review: should quinolones come first in Helicobacter pylori therapy? Therapeutic Advances in Gastroenterology. 2011;4(2):103–114.
    1. Peedikayil MC, Alsohaibani FI, Alkhenizan AH. Levofloxacin-based first-line therapy versus standard first-line therapy for Helicobacter pylori eradication: meta-analysis of randomized controlled trials. PLoS ONE. 2014;9(1)e85620
    1. Xiao SP, Gu M, Zhang GX. Is levofloxacin-based triple therapy an alternative for first-line eradication of Helicobacter pylori? A systematic review and meta-analysis. Scandinavian Journal of Gastroenterology. 2014;49:528–538.
    1. Molina-Infante J, Perez-Gallardo B, Fernandez-Bermejo M, et al. Clinical trial: clarithromycin vs. levofloxacin in first-line triple and sequential regimens for Helicobacter pylori eradication. Alimentary Pharmacology and Therapeutics. 2010;31(10):1077–1084.
    1. Gisbert JP, De La Morena F. Systematic review and meta-analysis: levofloxacin-based rescue regimens after Helicobacter pylori treatment failure. Alimentary Pharmacology and Therapeutics. 2006;23(1):35–44.
    1. Miehlke S, Krasz S, Schneider-Brachert W, et al. Randomized trial on 14 versus 7 days of esomeprazole, moxifloxacin, and amoxicillin for second-line or rescue treatment of Helicobacter pylori infection. Helicobacter. 2011;16(6):420–426.
    1. Cammarota G, Martino A, Pirozzi G, et al. High efficacy of 1-week doxycycline- and amoxicillin-based quadruple regimen in a culture-guided, third-line treatment approach for Helicobacter pylori infection. Alimentary Pharmacology & Therapeutics. 2004;19(7):789–795.
    1. Boyanova L. Prevalence of multidrug-resistant Helicobacter pylori in Bulgaria. Journal of Medical Microbiology. 2009;58(7):930–935.
    1. Mégraud F, Lehours P. Helicobacter pylori detection and antimicrobial susceptibility testing. Clinical Microbiology Reviews. 2007;20(2):280–322.
    1. Ierardi E, Giorgio F, Losurdo G, Leo AD, Principi M. As the increase in antibiotic resistances could change the treatment of helicobacter pylori infection: it will be a matter of geography? World Journal of Gastroenterology. 2013;19:8168–8180.
    1. Liou JM, Chen CC, Chang CY, et al. Efficacy of genotypic resistance-guided sequential therapy in the third-line treatment of refractory Helicobacter pylori infection: a multicentre clinical trial. Journal of Antimicrobial Chemotherapy. 2013;68:450–456.
    1. Matsuzaki J, Suzuki H, Nishizawa T, et al. Efficacy of sitafloxacin-based rescue therapy for Helicobacter pylori after failures of first- and second-line therapies. Antimicrobial Agents and Chemotherapy. 2012;56(3):1643–1645.
    1. Schabereiter-Gurtner C, Hirschl AM, Dragosics B, et al. Novel real-time PCR assay for detection of Helicobacter pylori infection and simultaneous clarithromycin susceptibility testing of stool and biopsy specimens. Journal of Clinical Microbiology. 2004;42(10):4512–4518.
    1. Liou JM, Chang CY, Sheng WH, et al. Genotypic resistance in Helicobacter pylori strains correlates with susceptibility test and treatment outcomes after levofloxacinand clarithromycin-based therapies. Antimicrobial Agents and Chemotherapy. 2011;55(3):1123–1129.
    1. Jeon CY, Calver AD, Victor TC, Warren RM, Shin SS, Murray MB. Use of fluoroquinolone antibiotics leads to tuberculosis treatment delay in a South African gold mining community. International Journal of Tuberculosis and Lung Disease. 2011;15(1):77–83.
    1. Devasia RA, Blackman A, Gebretsadik T, et al. Fluoroquinolone resistance in Mycobacterium tuberculosis: the effect of duration and timing of fluoroquinolone exposure. The American Journal of Respiratory and Critical Care Medicine. 2009;180(4):365–370.
    1. Tai WC, Hu TH, Lee CH, Chen HH, Huang CC, Chuah SK. Ano-perianal tuberculosis: 15 years of clinical experiences in Southern Taiwan. Colorectal Disease. 2010;12(7):e114–120.
    1. Chang WL, Kao CY, Wu CT, et al. Gemifloxacin can partially overcome quinolone resistance of H. pylori with gyrA mutation in Taiwan. Helicobacter. 2012;17(3):210–215.
    1. Kim SY, Yim J, Park JS, et al. Clinical effects of gemifloxacin on the delay of tuberculosis treatment. Journal of Korean Medical Science. 2013;28(3):378–382.

Source: PubMed

Sponsor e collaboratori

Condizioni mediche

Interventi farmacologici

3
Sottoscrivi